Nectar Lifesciences posts Rs 2.724 crore September profit

Nectar Lifesciences Limited posted a consolidated profit of Rs 2.724 crore for the quarter ended September 30, 2026, reversing a Rs 15.3977 crore loss in the preceding quarter, as other income reached Rs 14.0571 crore while sales were Rs 1.10 lakh. The Board approved the unaudited results on November 14, 2026.

How did Nectar Lifesciences return to profit in September 2026?

Nectar Lifesciences returned to consolidated profit as total income rose to Rs 14.0681 crore in the September 2026 quarter while total expenses fell to Rs 6.7961 crore, resulting in Rs 7.272 crore profit before tax from continuing operations. In the June 2026 quarter, total income was Rs 3.362 crore and expenses were Rs 27.9815 crore, resulting in a Rs 24.6195 crore pre-tax loss from continuing operations.

Profit after tax from continuing operations was Rs 3.5636 crore in September, compared with a Rs 15.7187 crore loss in June. September included a deferred-tax expense of Rs 3.7084 crore, whereas June had a deferred-tax credit of Rs 8.9008 crore; neither quarter recorded current tax. The following comparison covers continuing operations only.

Consolidated profit was lower than the continuing-operations result because discontinued operations recorded an Rs 83.96 lakh post-tax loss in September. In June, discontinued operations generated Rs 32.10 lakh post-tax profit, but this did not offset the continuing-operations loss. Basic and diluted earnings per share, or EPS, for continuing and discontinued operations combined were Rs 0.14 in September, against a loss per share of Rs 0.79 in June.

What drove Nectar Lifesciences' September-quarter income?

Nectar Lifesciences derived nearly all its Rs 14.0681 crore September-quarter total income from Rs 14.0571 crore of other income, while income from operations sales was Rs 1.10 lakh and other operating income was nil. The results do not provide a component-wise explanation for the other-income line, so they do not establish its recurring operating nature.

The income mix changed from June, when other income was Rs 2.9199 crore, sales were Rs 1.45 lakh and other operating income was Rs 42.76 lakh. In the restated September 2025 quarter, other income was Rs 2.62 lakh and other operating income was Rs 71.45 lakh. Total income consequently increased from Rs 74.07 lakh a year earlier to Rs 14.0681 crore in September 2026.

Nectar Lifesciences states that it is exclusively in the pharmaceutical business segment, although continuing-operations sales were Rs 1.10 lakh in the quarter. The capsule business is presented as discontinued operations under Indian Accounting Standard, or Ind AS, 105 on assets held for sale and discontinued operations. That classification means the continuing-operations comparison excludes the capsule business figures.

For the half year ended September 30, 2026, other income was Rs 16.977 crore and total income was Rs 17.4301 crore, compared with Rs 32.93 lakh and Rs 1.0501 crore, respectively, in the restated prior-year half. Despite the income increase, continuing operations recorded a Rs 12.1551 crore post-tax loss for the latest six-month period, compared with a Rs 39.04 lakh profit a year earlier.

Which expenses changed at Nectar Lifesciences during the quarter?

Nectar Lifesciences reduced other expenses to Rs 5.784 crore in September from Rs 26.6366 crore in June, a decrease of Rs 20.8526 crore that accounted for most of the overall expense movement. Employee-benefit expense declined to Rs 88.95 lakh from Rs 1.0637 crore, while finance costs changed from Rs 15.69 lakh to a Rs 0.01 lakh credit.

Depreciation and amortisation were Rs 10.89 lakh in September and Rs 11.06 lakh in June. The September result included an Rs 1.38 lakh expense from changes in inventories, whereas June reported an Rs 1.38 lakh credit in that line. There was no cost of materials consumed in either quarter, and purchases of stock in trade were nil in September after Rs 2.75 lakh in June.

Against the restated September 2025 quarter, total expenses increased from Rs 27.60 lakh to Rs 6.7961 crore, including a rise in other expenses from Rs 14.46 lakh to Rs 5.784 crore. Total income, however, rose more sharply, from Rs 74.07 lakh to Rs 14.0681 crore. Continuing-operations profit before tax therefore increased from Rs 46.47 lakh to Rs 7.272 crore.

The September results included no exceptional item in either continuing or discontinued operations. This contrasts with the year ended March 31, 2026, when discontinued operations included an Rs 163.3732 crore exceptional gain on slump sale. The September consolidated profit was therefore derived from the reported income, expense and tax lines rather than an exceptional gain.

How did discontinued operations affect Nectar Lifesciences' profit?

Nectar Lifesciences reported an Rs 83.96 lakh post-tax loss from discontinued operations in the September quarter, reducing total profit from Rs 3.5636 crore for continuing operations to Rs 2.724 crore. The discontinued business recorded Rs 1.6103 crore of revenue from operations, Rs 1.62 lakh of other income and Rs 2.9172 crore of total expenses.

The discontinued operations include the capsule business, for which Nectar Lifesciences entered a Business Transfer Agreement with Capnest Health Care Private Limited on December 20, 2025. The agreement provides for consideration of Rs 19.90 crore, including related receivables and payables or creditors, subject to working-capital adjustments and approval under the Himachal Pradesh Tenancy and Land Reforms Act, 1972.

Fixed assets at the inoperative Jammu unit were disposed of during the period, with the financial impact disclosed in the results. For the half year ended September 30, 2026, discontinued operations made an Rs 51.86 lakh post-tax loss, compared with a restated Rs 239.6269 crore loss in the corresponding prior-year half.

Nectar Lifesciences also said that a portion of vacant land near Garhshankar, Punjab, was sold in the September quarter. Management expects to sell the balance by the end of the financial year as part of its non-core asset monetisation. The results do not disclose the value of land sold during the quarter.

What do the investment losses and subsidiary disclosures show?

Nectar Lifesciences disclosed a Rs 26.725 crore loss on mutual fund, exchange-traded fund, or ETF, and equity instruments for the half year ended September 30, 2026. Of this amount, Rs 25.1329 crore had been incurred up to June 30, 2026. The company said it recognised the impact in profit or loss under Ind AS 109, which covers financial instruments.

Nectar Lifesciences said it deployed surplus funds in mutual funds, ETFs and equities during the year, and that prevailing market conditions and geopolitical developments adversely affected their value. The results do not provide a line-by-line reconciliation between this investment-loss disclosure and the Rs 14.0571 crore other-income line reported for the September quarter.

The consolidated accounts include two wholly owned subsidiaries: Neclife PT, Unipessoal LDA, which remained inoperative, and Avensis Exports Private Limited. The auditors said unaudited interim information for a subsidiary showed nil revenue and an Rs 2.2209 crore net loss for the September quarter, while management considered that information not material to the group.

The statutory auditors issued a limited-review conclusion on the unaudited consolidated results. They said nothing had come to their attention indicating that the statement had not disclosed the required information under applicable listing regulations. The audit committee and Board reviewed the September-quarter and half-year results on November 14, 2026.

Conclusion

Nectar Lifesciences moved from a Rs 15.3977 crore consolidated loss in June 2026 to a Rs 2.724 crore September profit, supported by Rs 14.0571 crore of other income and a Rs 20.8526 crore reduction in other expenses. Continuing operations generated Rs 3.5636 crore post-tax profit, while the Rs 83.96 lakh loss from discontinued operations reduced the consolidated result.

The next disclosures to watch are progress on the Rs 19.90 crore capsule-business transfer, management's planned sale of the remaining Garhshankar land by the end of the financial year, and projects being evaluated under the amended real-estate object clause. Nectar Lifesciences also disclosed Rs 26.725 crore of investment losses for the first half, making subsequent investment performance relevant to future results.